|
|
Article: Aduro Biotech Completes Series A-1 Financing.
- Article from:
- Business Wire
- Article date:
- November 11, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Company Will Use Funds to Advance Vaccine Platform for Infectious Disease and Cancer Immunotherapy
BERKELEY, Calif. -- Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing. Individual investors, including senior management of the company, provided a $2 million equity round. Aduro has also secured an additional $2.7 million in funding through grants and contracts from the Department of Defense for development of a therapeutic vaccine for Hepatitis C, and from ...
Related newspaper, magazine, and journal articles:
|
|
Article: OMRON Acquires US Optical Interface Module Maker Aduro
JCNN News Summaries - Japan Corporate News Network;
January 13, 2006 ;
309 words
... ... Jan 13, 2006 - (JCN) - OMRON has announced that it acquired Aduro, a California-based high-speed optical interface module ... company OMRON Management Center of America on December 1, 2005. Aduro was acquired through OMRON Network Products. The new company ...
|
|